University of Groningen
CRISPR/Cas9 and targeted cancer therapy
Liu, Bin
DOI:
10.33612/diss.99103461
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Liu, B. (2019). CRISPR/Cas9 and targeted cancer therapy. University of Groningen.
https://doi.org/10.33612/diss.99103461
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
CRISPR/Cas9 and targeted cancer
therapy
The research described in this thesis was carried out at the department of Chemical and Pharmcetical Biology at the University of Groningen.
The research was crried out according to the rquirements of the Graduate School of Science, Faculty of Science and Engineering, University of Groningen, The Netehrlands
Printing of this thesis was financially supported by the University Library and the Graduate School of Science, University of Groningen, The Netherlands.
Printing: Ridderprint BV | www.ridderprint.nl
IBSN (ebook): 978-94-6375-611-2 IBSN (printed version): 978-94-6375-610-5
Copyright © 2019 Bin Liu. All rights are reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without the prior permission in writing of the author.
CRISPR/Cas9 and targeted cancer
therapy
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. C. Wijmenga
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Tuesday 29 October 2019 at 11.00 hours
by
Bin Liu
born on 16 February 1989 in Jiangsu, China
The research described in this thesis was carried out at the department of Chemical and Pharmcetical Biology at the University of Groningen.
The research was crried out according to the rquirements of the Graduate School of Science, Faculty of Science and Engineering, University of Groningen, The Netehrlands
Printing of this thesis was financially supported by the University Library and the Graduate School of Science, University of Groningen, The Netherlands.
IBSN (ebook): 978-94-6375-611-2 IBSN (printed version): 978-94-6375-610-5
Copyright © 2019 Bin Liu. All rights are reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without the prior permission in writing of the author.
CRISPR/Cas9 and targeted cancer
therapy
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. C. Wijmenga
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Tuesday 29 October 2019 at 11.00 hours
by
Bin Liu
born on 16 February 1989 in Jiangsu, China
Supervisors
Prof. H.J. Haisma Prof. F.J. Dekker
Assessment Committee
Prof. M. Schmidt
Prof. V.W. van Beusechem Prof. F. Foijer
Contents
Chapter 1 Scope and outline of this thesis ... 7 Chapter 2 CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment... 17 Chapter 3 CRISPR/Cas9 for overcoming drug resistance in solid tumors... 75 Chapter 4 Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and
tyrosine kinase inhibitor resistance in non-small cell lung carcinoma ... 101 Chapter 5 CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung
Cancer upon Loss of Epidermal Growth Factor Receptor... 135 Chapter 6 CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation ... 171 Chapter 7 Inhibition of Histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome
editing ... 195 Chapter 8 Summary and Future Perspectives ... 236
Appendices Acknowledgement List of publication About the author
Supervisors
Prof. H.J. Haisma Prof. F.J. Dekker
Assessment Committee
Prof. M. Schmidt
Prof. V.W. van Beusechem Prof. F. Foijer
Contents
Chapter 1 Scope and outline of this thesis ... 7 Chapter 2 CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment ... 17 Chapter 3 CRISPR/Cas9 for overcoming drug resistance in solid tumors ... 75 Chapter 4 Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and
tyrosine kinase inhibitor resistance in non-small cell lung carcinoma ... 101 Chapter 5 CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung
Cancer upon Loss of Epidermal Growth Factor Receptor ... 135 Chapter 6 CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation ... 171 Chapter 7 Inhibition of Histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome
editing ... 195 Chapter 8 Summary and Future Perspectives ... 236
Appendices Acknowledgement List of publication About the author
